Adalimumab-induced severe atopic dermatitis with secondary multidrug-resistant bacterial infection
10.3760/cma.j.cn114015-20231222-00926
- VernacularTitle:阿达木单抗致重度特应性皮炎继发多重耐药菌感染
- Author:
Jingrong QU
1
;
Lei ZHANG
Author Information
1. 山东省诸城市人民医院临床药学科，诸城 262200
- Publication Type:Journal Article
- Keywords:
Dermatitis, atopic;
Adalimumab;
Tumor necrosis factor inhibitors;
Drug-related side effects and adverse reactions;
Multidrug-resistant bacterial infection
- From:
Adverse Drug Reactions Journal
2024;26(9):571-573
- CountryChina
- Language:Chinese
-
Abstract:
A 15-year-old female child with juvenile idiopathic arthritis for 10 years received methotrexate combined with adalimumab (80 mg by subcutaneous injection once every 2 weeks) 2 years ago. After 1.5 years of treatments, red papules appeared on the skin of the perineum and thigh, accompanied by itching. The rash gradually spread to multiple parts of the body, including the head, neck, and limbs, with plaques and scales, and the rash on both calve ruptures and oozes, accompanied by itching and pain. It was considered to be severe atopic dermatitis caused by adalimumab based on skin pathological results, elevated serum immunoglobulin E, and clinical signs. The results of the patient′s wound secretion culture indicated a mixed infection of resistant bacteria such as Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus faecalis. After discontinuing adalimumab and receiving systemic treatments with anti-allergic and sensitive antibiotics, as well as local treatment with glucocorticoids for 14 days, the rash and infection were improved. At the six-month of follow-up, the patient′s skin lesions were basically healed.
